Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, has announced its participation in the Stifel 2024 Healthcare Conference. CEO Claire Mazumdar will deliver a presentation on November 19, 2024 at 9:10 a.m. ET in New York. The presentation will be accessible via live webcast on Bicara's website, with a replay available for approximately 90 days afterward.
Bicara Therapeutics (Nasdaq: BCAX), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie bifunzionali per i tumori solidi, ha annunciato la sua partecipazione alla Stifel 2024 Healthcare Conference. Il CEO Claire Mazumdar terrà una presentazione il 19 novembre 2024 alle 9:10 a.m. ET a New York. La presentazione sarà accessibile tramite webcast in diretta sul sito web di Bicara, con una registrazione disponibile per circa 90 giorni successivi.
Bicara Therapeutics (Nasdaq: BCAX), una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de terapias bifuncionales para tumores sólidos, ha anunciado su participación en la Stifel 2024 Healthcare Conference. La CEO Claire Mazumdar dará una presentación el 19 de noviembre de 2024 a las 9:10 a.m. ET en Nueva York. La presentación estará disponible a través de una transmisión en vivo en el sitio web de Bicara, con una repetición disponible durante aproximadamente 90 días después.
비카라 제약 (Nasdaq: BCAX)은 고형 종양에 대한 이중 기능 요법 개발에 집중하는 임상 단계의 생명공학 회사로, 스티펠 2024 헬스케어 컨퍼런스에 참가할 것이라고 발표했습니다. CEO 클레어 마줌다르는 2024년 11월 19일 오전 9시 10분 ET에 뉴욕에서 발표를 할 예정입니다. 발표는 비카라 웹사이트에서 실시간 웹캐스트를 통해 접근할 수 있으며, 이후 약 90일 동안 재생 가능할 것입니다.
Bicara Therapeutics (Nasdaq: BCAX), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies bifonctionnelles pour les tumeurs solides, a annoncé sa participation à la Stifel 2024 Healthcare Conference. La PDG Claire Mazumdar fera une présentation le 19 novembre 2024 à 9h10 ET à New York. La présentation sera accessible par webcast en direct sur le site web de Bicara, avec une rediffusion disponible pendant environ 90 jours par la suite.
Bicara Therapeutics (Nasdaq: BCAX), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von bifunktionalen Therapien für solide Tumoren spezialisiert hat, hat seine Teilnahme an der Stifel 2024 Healthcare Conference angekündigt. CEO Claire Mazumdar wird am 19. November 2024 um 9:10 Uhr ET in New York eine Präsentation halten. Die Präsentation wird über einen Live-Stream auf der Website von Bicara zugänglich sein, mit einer Wiederholung, die etwa 90 Tage danach verfügbar ist.
- None.
- None.
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present at the Stifel 2024 Healthcare Conference in New York, NY on Tuesday, November 19, 2024 at 9:10 a.m. ET.
A live webcast of the presentation will be available on the Events and Presentations section of Bicara’s website at www.bicara.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Contacts
Investors
Rachel Frank
IR@bicara.com
Media
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When is Bicara Therapeutics (BCAX) presenting at the Stifel 2024 Healthcare Conference?
How can I watch Bicara Therapeutics' (BCAX) presentation at the Stifel 2024 Healthcare Conference?
What type of therapies does Bicara Therapeutics (BCAX) develop?
Who will represent Bicara Therapeutics (BCAX) at the Stifel 2024 Healthcare Conference?
